The Gastrointestinal Stromal Tumor Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Gastrointestinal Stromal Tumor Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Gastrointestinal Stromal Tumor Market.

Some of the key takeaways from the Gastrointestinal Stromal Tumor Pipeline Report:

• Companies across the globe are diligently working toward developing novel Gastrointestinal Stromal Tumor treatment therapies with a considerable amount of success over the years. 
• Gastrointestinal Stromal Tumor companies working in the treatment market are IDRx, Inc., Theseus Pharmaceuticals, Novartis, Arog Pharmaceuticals, Inc., Jiangsu HengRui Medicine Co., Ltd., Cogent Biosciences, Inc., and others, are developing therapies for the Gastrointestinal Stromal Tumor treatment 

• Emerging Gastrointestinal Stromal Tumor therapies in the different phases of clinical trials are- IDRX-42, THE-630, PDR001, Crenolanib, Famitinib, CGT9486, and others are expected to have a significant impact on the Gastrointestinal Stromal Tumor market in the coming years.   
• In January 2022, A Phase III open-label, global, multicenter research of CGT9486 in conjunction with sunitinib was started by Cogent Biosciences, Inc
• In June 2022, The US Food and Drug Administration (FDA) gave Immunicum AB’s ilixadencel an Orphan Drug Designation (ODD) for the management of Gastrointestinal Stromal Tumours (GIST).
• The selective tyrosine kinase inhibitor PLX9486 is intended to effectively inhibit D816V and other KIT exon 17 mutations. It is challenging to obtain wide therapeutic KIT inhibition since the majority of patients with imatinib-resistant GIST have both primary and secondary KIT mutations, frequently including secondary mutations on exon 17 and exon 13. In the first half of 2023, Cogent Biosciences, Inc. will present preliminary findings from PEAK, a registrational randomised, open-label, international Phase III clinical trial for patients with gastrointestinal stromal tumours (GIST)
• In June 2022, The third-generation tyrosine kinase inhibitor (TKI) olverembatinib (HQP1351) was studied in a Phase Ib/II research in patients with metastatic gastrointestinal stromal tumours (GIST) who had either failed or been resistant to earlier TKI treatment. The results were released by Ascentage Pharma. Olverembatinib (HQP1351), according to the manufacturer, showed encouraging anticancer efficacy in patients with gastrointestinal stromal tumours (GIST) that were resistant to tyrosine kinase inhibitors (TKIs) but low in succinate dehydrogenase (SDH). Ascentage Pharma and Innovent Biologics (1801.HK) agreed to work together to develop and market olverembatinib for the treatment of cancer in China in July 2021
• In August 2021, Bezuclastinib/CGT9486 received orphan drug designation from the FDA for use in gastrointestinal stromal tumours.Bezuclastinib was given orphan drug status by the FDA for the treatment of GIST, which is thought to affect between 4,000 and 6,000 people annually in the United States. In the second half of 2021, Cogent is still on pace to begin a new research including bezuclastinib and sunitinib for GIST patients

Gastrointestinal Stromal Tumor Overview

The uncommon cancer known as a gastrointestinal stromal tumour (GIST) affects the abdomen’s digestive system or surrounding structures. Interstitial cells of Cajal (ICCs) are the source of this sarcoma, however it can also originate from less differentiated stem cells or precursor cells.

Get a Free Sample PDF Report to know more about Gastrointestinal Stromal Tumor Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-pipeline-insight

Emerging Gastrointestinal Stromal Tumor Drugs Under Different Phases of Clinical Development Include:

• IDRX-42: IDRx, Inc.
• THE-630: Theseus Pharmaceuticals
• PDR001: Novartis
• Crenolanib: Arog Pharmaceuticals, Inc.
• Famitinib: Jiangsu HengRui Medicine Co., Ltd.
• CGT9486: Cogent Biosciences, Inc.

Route of Administration

Gastrointestinal Stromal Tumor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Gastrointestinal Stromal Tumor Pipeline Therapeutics Assessment

• Gastrointestinal Stromal Tumor Assessment by Product Type
• Gastrointestinal Stromal Tumor By Stage and Product Type
• Gastrointestinal Stromal Tumor Assessment by Route of Administration
• Gastrointestinal Stromal Tumor By Stage and Route of Administration
• Gastrointestinal Stromal Tumor Assessment by Molecule Type
• Gastrointestinal Stromal Tumor by Stage and Molecule Type

DelveInsight’s Gastrointestinal Stromal Tumor Report covers around 28+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Gastrointestinal Stromal Tumor product details are provided in the report. Download the Gastrointestinal Stromal Tumor pipeline report to learn more about the emerging Gastrointestinal Stromal Tumor therapies

Some of the key companies in the Gastrointestinal Stromal Tumor Therapeutics Market include:

Key companies developing therapies for Gastrointestinal Stromal Tumor are – Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, Ascentage Pharma, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics, and others.

Gastrointestinal Stromal Tumor Pipeline Analysis:

The Gastrointestinal Stromal Tumor pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Gastrointestinal Stromal Tumor with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gastrointestinal Stromal Tumor Treatment.
• Gastrointestinal Stromal Tumor key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Gastrointestinal Stromal Tumor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gastrointestinal Stromal Tumor market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Gastrointestinal Stromal Tumor drugs and therapies

Gastrointestinal Stromal Tumor Pipeline Market Drivers

• Increasing prevalence of digestive disorders, increasing investment of biotechnology and pharmaceutical industries in research and development, availability of funds is likely to drive the growth of the Gastrointestinal Stromal Tumor are some of the important factors that are fueling the Gastrointestinal Stromal Tumor Market.

Gastrointestinal Stromal Tumor Pipeline Market Barriers

• However, higher cost associated with the treatment procedure and hence, this is a major fact that might be responsible for slowing the market growth, reimbursement Policies and other factors are creating obstacles in the Gastrointestinal Stromal Tumor Market growth.

Scope of Gastrointestinal Stromal Tumor Pipeline Drug Insight    

• Coverage: Global
• Key Gastrointestinal Stromal Tumor Companies: IDRx, Inc., Theseus Pharmaceuticals, Novartis, Arog Pharmaceuticals, Inc., Jiangsu HengRui Medicine Co., Ltd., Cogent Biosciences, Inc., and others
• Key Gastrointestinal Stromal Tumor Therapies: IDRX-42, THE-630, PDR001, Crenolanib, Famitinib, CGT9486, and others
• Gastrointestinal Stromal Tumor Therapeutic Assessment: Gastrointestinal Stromal Tumor current marketed and Gastrointestinal Stromal Tumor emerging therapies
• Gastrointestinal Stromal Tumor Market Dynamics: Gastrointestinal Stromal Tumor market drivers and Gastrointestinal Stromal Tumor market barriers 

Request for Sample PDF Report for Gastrointestinal Stromal Tumor Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services